Molecular Partners Announces Collaboration With Novartis to Develop Two DARPin(R) Therapies Designed for Potential Use Against COVID-19
The Pharma Data
OCTOBER 27, 2020
Molecular Partners, a global leader in the development of DARPinĀ® therapeutics, will be responsible for the conduct of phase 1 & 2 trials that may lead to emergency use approval; Novartis will be responsible for further development, manufacturing, distribution and commercialization.
Let's personalize your content